Welcome to the new Regeneron Newsroom. This newsroom is designed to provide members of the media with easy access to up-to-date information about the Company.
For an e-mail response to questions about Regeneron, please contact us at media@regeneron.com .
Jun 6, 2013
Regeneron and Bayer Report Positive Phase 3 Results for EYLEA® (aflibercept) Injection in Myopic Choroidal Neovascularization (mCNV)
May 21, 2013
Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
May 15, 2013
Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
May 8, 2013
Regeneron Announces Upcoming 2013 Investor Conference Presentations
May 3, 2013
Regeneron Reports First Quarter 2013 Financial and Operating Results
May 3, 2013
Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs
Apr 18, 2013
Regeneron Announces Upcoming 2013 Investor Conference Presentations
Apr 11, 2013
Regeneron to Report First Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2013
Apr 4, 2013
Regeneron Pharmaceuticals Announces Expansion in New York's Hudson Valley
Mar 4, 2013
Regeneron Announces Potential Additional Royalty Stream Related to EU Approval for Ilaris® (canakinumab) in Patients Suffering Acute Gouty Arthritis Attacks Who Cannot Gain Relief From Current Treatments
Shareholder Briefcase
E-mail Alerts
Download Library
REGN Snapshot
RSS News Feeds
